Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer HealthCare AG
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Exploring the efficacy and safety of rivaroxaban to support elective percutaneous coronary intervention
The aim of this study is to assess whether rivaroxaban, as compared to unfractionated heparin, on the background of standard dual antiplatelet therapy (DAPT), can effectively suppress thrombosis, and ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH
to evaluate the long-term safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in treatment of naive patients and patients pretreated with an Endothelin Receptor Antagonist...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
An uncontrolled open label multicenter phase II safety study of BAY 73-4506 in patients with hepatocellular carcinoma (HCC)
To assess the safety profile of BAY 73-4506 in patients with hepatocellular carcinoma (HCC)
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A 54 week treatment, randomized, multi center, double blind, placebo controlled study to assess the safety and efficacy of NEBIDO 1000 mg (4 ml) in elderly men with symptomatic late onset hypogonadism (SLOH)
Efficacy and safety of NEBIDO in men with symptomatic late onset hypogonadism (SLOH) as characterized in the protocol inclusion criteria: To assess the change from baseline in lean body mass after ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A clinical trial to investigate if different doses of BAY 85-3934 are safe and effective in patients with anaemia due to chronic kidney disease, who have not received any previous treatment to help produce red blood cells and are not undergoing dialysis treatment. Ensayo Clinico para investigar la seguridad y efectividad de diferentes dosis de BAY 85-3934, en pacientes con anemia por enfermedad renal crónica, que no han recibido tratamiento previo para ayudar a producir globulos rojos y que no están en tratamiento de dialisis
To evaluate the efficacy for up to 16 weeks of fixed dose treatment with BAY 85-3934 versus placebo as measured by haemoglobin (Hb) levels. Evaluar la eficacia durante 16 semanas del tratamiento...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Phase III Trial Comparing Capecitabine in Combination with Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
The objective of this phase-III trial is to compare the efficacy and safety of sorafenib in combination with capecitabine versus capecitabine in combination with placebo in the treatment of subjects w...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema
To assess the efficacy of intravitreally (IVT) administered VEGF Trap Eye in comparison to laser treatment in improving best corrected visual acuity (BCVA) in subjects with diabetic macular edema (DME...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Single-center, randomized, placebo-controlled, double-blind, parallel group study to evaluate whether a single-dose of either 20 mg piroxicam, 40 mg piroxicam or 80 mg piroxicam shows an effect on ovulation after the onset of LH surge compared to placebo in healthy young women
To assess whether piroxicam has an effect on ovulation (delay or inhibition) when given after the onset of LH surge
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Rivaroxaban for treatment in venous thrombosis in children
The primary objective is: • to assess the incidence of major bleeding and clinically relevant non-major bleeding
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Safety of Primovist / Eovist in Renally Impaired patients
The primary objective is to assess the magnitude of potential risk of developing NSF with the administration of Primovist/Eovist in patients with moderate to severe renal impairment for the developmen...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next